US Patent

US11304961 — Compositions comprising dexamethasone

Method of Use · Assigned to Dexcel Pharma Technologies Ltd · Expires 2037-12-18 · 12y remaining

Vulnerability score 53/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a pharmaceutical composition that includes high-dose dexamethasone for treating multiple myeloma in combination with an anti-cancer drug.

USPTO Abstract

A pharmaceutical composition useful for the treatment of multiple myeloma in combination with an anti-cancer drug is provided. The pharmaceutical composition includes high-dose dexamethasone or a pharmaceutically acceptable salt or solvate thereof.

Drugs covered by this patent

Decadron (dexamethasone) · Generic (originally Merck)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3344`	—	Decadron

Patent Metadata

Patent number: US11304961
Jurisdiction: US
Classification: Method of Use
Expires: 2037-12-18
Drug substance claim: No
Drug product claim: Yes
Assignee: Dexcel Pharma Technologies Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.